Pear Therapeutics (PEAR) vs. Its Competitors Financial Contrast

Pear Therapeutics (NASDAQ:PEARGet Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it contrast to its competitors? We will compare Pear Therapeutics to similar companies based on the strength of its dividends, institutional ownership, profitability, valuation, risk, analyst recommendations and earnings.

Institutional and Insider Ownership

55.4% of Pear Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all “Health services” companies are held by institutional investors. 30.7% of Pear Therapeutics shares are held by insiders. Comparatively, 21.6% of shares of all “Health services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pear Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pear Therapeutics -265.26% -185.33% -85.47%
Pear Therapeutics Competitors -325.87% -481.74% -38.64%

Risk and Volatility

Pear Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Pear Therapeutics’ competitors have a beta of 1.48, indicating that their average share price is 48% more volatile than the S&P 500.

Valuation & Earnings

This table compares Pear Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pear Therapeutics $4.21 million -$65.14 million -8.68
Pear Therapeutics Competitors $1.36 billion -$98.47 million 30.54

Pear Therapeutics’ competitors have higher revenue, but lower earnings than Pear Therapeutics. Pear Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pear Therapeutics and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pear Therapeutics 0 1 5 0 2.83
Pear Therapeutics Competitors 7 130 275 0 2.65

Pear Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 227.23%. As a group, “Health services” companies have a potential upside of 84.29%. Given Pear Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Pear Therapeutics is more favorable than its competitors.

Summary

Pear Therapeutics beats its competitors on 8 of the 12 factors compared.

Pear Therapeutics Company Profile

(Get Rating)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.